Comparison of clinical efficacy, immune response and postoperative adverse reactions of transurethral holmium laser lithotripsy and percutaneous nephrolithotomy in elderly patients with complex upper urinary tract renal calculi: a retrospective cohort study

比较经尿道钬激光碎石术和经皮肾镜取石术治疗老年复杂性上尿路肾结石患者的临床疗效、免疫反应和术后不良反应:一项回顾性队列研究

阅读:1

Abstract

OBJECTIVES: This study aimed to evaluate the clinical efficacy, immune response, and postoperative adverse effects of transurethral holmium laser lithotripsy (RIRS) vs. percutaneous nephrolithotomy (PCNL) in elderly patients with complex upper urinary tract renal calculi. METHODS: A retrospective analysis was conducted on 70 elderly patients treated from January 2020 to January 2021. The control group (n = 32) underwent PCNL, while the observation group (n = 38) received transurethral holmium laser lithotripsy. Pre- and post-operative comparisons included serum creatinine (Scr), cystatin-C, kidney injury molecule-1 (KIM-1), immune indices, thyroxine (TH), and urokinase (UK). Stone clearance rates and adverse reactions were also assessed. RESULTS: The observation group showed less bleeding, shorter hospital stays, higher hemoglobin decrease, and longer operation time (P < 0.05). Higher stone clearance rates were observed in the RIRS group at 86.84% and 76.32% for first and second stages, compared to 65.64% and 53.13% in the PCNL group. Postoperatively, Scr, Cys-C, and KIM-1 levels were lower in the RIRS group. Both groups exhibited decreased CD4+ and CD4+/CD8+, increased CD8+, reduced TH, and elevated UK levels post-surgery (P < 0.05). Adverse reactions were similar between groups. CONCLUSIONS: For elderly patients with complex renal calculi, transurethral holmium laser lithotripsy offers superior stone clearance and reduced renal damage compared to PCNL, despite a longer operation time. Consideration of individual patient conditions is crucial for selecting the optimal procedure.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。